Atorvia is early-stage biotech on a mission to end organ failure. With a key focus on proteomics, and assisted by machine learning tools, Atorvia is developing novel treatments targeting the regulated cell death pathway that causes organ failure. Atorvia’s first therapeutic is at the lead identification stage with a first indication in kidney to prevent and treat Acute Kidney Injury – a common complication that occurs in tens of millions of patients each year and which currently lack treatment options. Many of these patients require dialysis and experience long-term health complications such as heart disease and diabetes – even from a single, temporary episode of kidney failure. Atorvia is on a mission to end this.